Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia

Matteo Passerini; Tamar Ratishvili; Jonathon M. Monroe; Zelalem Temesgen; Thomas E. Witzig; Neil E. Kay; Richard B. Kennedy; Sameer A. Parikh

doi:10.1080/10428194.2023.2183730

Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia

Matteo Passerini, Tamar Ratishvili, Jonathon M. Monroe, Zelalem Temesgen, Thomas E. Witzig, Neil E. Kay, Richard B. Kennedy, Sameer A. Parikh

Research output: Contribution to journal › Article › peer-review

Abstract

We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose. The proportion of positive cellular response against the peptide pool covering the full-length Wuhan-Hu-1 spike protein was similar between untreated and treated CLL patients at all three timepoints. The cellular response to the mutated regions of BA.2 spike protein was lower than the response to the corresponding regions in the ancestral spike after the second dose, but this difference was eliminated after the third dose.

Original language	English (US)
Pages (from-to)	874-883
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	64
Issue number	4
DOIs	https://doi.org/10.1080/10428194.2023.2183730
State	Published - 2023

Keywords

CLL
Omicron
cellular response
vaccination

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2023.2183730

Cite this

Passerini, M., Ratishvili, T., Monroe, J. M., Temesgen, Z., Witzig, T. E., Kay, N. E., Kennedy, R. B., & Parikh, S. A. (2023). Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 64(4), 874-883. https://doi.org/10.1080/10428194.2023.2183730

@article{ccc1ce39b8af46baab4375223b44c5be,

title = "Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia",

abstract = "We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose. The proportion of positive cellular response against the peptide pool covering the full-length Wuhan-Hu-1 spike protein was similar between untreated and treated CLL patients at all three timepoints. The cellular response to the mutated regions of BA.2 spike protein was lower than the response to the corresponding regions in the ancestral spike after the second dose, but this difference was eliminated after the third dose.",

keywords = "CLL, Omicron, cellular response, vaccination",

author = "Matteo Passerini and Tamar Ratishvili and Monroe, {Jonathon M.} and Zelalem Temesgen and Witzig, {Thomas E.} and Kay, {Neil E.} and Kennedy, {Richard B.} and Parikh, {Sameer A.}",

note = "Publisher Copyright: {\textcopyright} 2023 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/10428194.2023.2183730",

language = "English (US)",

volume = "64",

pages = "874--883",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia

AU - Passerini, Matteo

AU - Ratishvili, Tamar

AU - Monroe, Jonathon M.

AU - Temesgen, Zelalem

AU - Witzig, Thomas E.

AU - Kay, Neil E.

AU - Kennedy, Richard B.

AU - Parikh, Sameer A.

PY - 2023

Y1 - 2023

N2 - We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose. The proportion of positive cellular response against the peptide pool covering the full-length Wuhan-Hu-1 spike protein was similar between untreated and treated CLL patients at all three timepoints. The cellular response to the mutated regions of BA.2 spike protein was lower than the response to the corresponding regions in the ancestral spike after the second dose, but this difference was eliminated after the third dose.

AB - We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose. The proportion of positive cellular response against the peptide pool covering the full-length Wuhan-Hu-1 spike protein was similar between untreated and treated CLL patients at all three timepoints. The cellular response to the mutated regions of BA.2 spike protein was lower than the response to the corresponding regions in the ancestral spike after the second dose, but this difference was eliminated after the third dose.

KW - CLL

KW - Omicron

KW - cellular response

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85150662294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150662294&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2183730

DO - 10.1080/10428194.2023.2183730

M3 - Article

C2 - 36908110

AN - SCOPUS:85150662294

SN - 1042-8194

VL - 64

SP - 874

EP - 883

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -

Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this